Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study
- Resource Type
- Article
- Source
- In
Oral Oncology July 2022 130 - Subject
- Language
- ISSN
- 1368-8375